Related Experiment Video
Updated: Aug 14, 2026
08:49
Presynaptic Dopamine Dynamics in Striatal Brain Slices with Fast-scan Cyclic Voltammetry
Published on: January 12, 2012
Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex
M Sakaue1, P Somboonthum, B Nishihara
1Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamado-oka, Suita, Osaka 565-0871 Japan.
British Journal of Pharmacology
|March 1, 2000
Summary
Activation of serotonin 5-HT(1A) receptors increases dopamine release in specific brain regions, particularly the prefrontal cortex. This finding clarifies the mechanism by which serotonin influences dopamine signaling in the brain.
Area of Science:
- Neuroscience
- Pharmacology
- Neurochemistry
Background:
- Serotonin (5-Hydroxytryptamine, 5-HT) influences dopamine (3,4-dihydroxyphenylethylamine) neuron activity.
- The specific role of 5-HT(1A) receptors in regulating dopamine release remains unclear.
Purpose of the Study:
- To investigate the effect of a selective 5-HT(1A) receptor agonist, MKC-242, on dopamine release in the rat prefrontal cortex.
- To elucidate the mechanism of 5-HT(1A) receptor-mediated dopamine release.
Main Methods:
- Microdialysis in freely moving rats to measure extracellular dopamine levels.
- Administration of MKC-242 (5-HT(1A) agonist) and WAY100635 (5-HT(1A) antagonist).
- Intracerebroventricular injection of 5,7-dihydroxytryptamine to deplete serotonin.
Main Results:
- MKC-242 significantly increased dopamine release in the prefrontal cortex and hippocampus, but not in the striatum or nucleus accumbens.
- The effect of MKC-242 was blocked by the 5-HT(1A) antagonist WAY100635.
- Serotonin depletion did not abolish the effect of MKC-242, suggesting postsynaptic receptor involvement.
Conclusions:
- Activation of postsynaptic 5-HT(1A) receptors stimulates dopamine release.
- This effect is region-specific within the brain.
- Findings provide insight into the neurochemical pathways linking serotonin and dopamine systems.
Related Concept Videos
01:29Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:27Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...